日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world experience with teplizumab in stage 2 type 1 diabetes: a plain language summary

teplizumab 在 1 型糖尿病 2 期治疗中的真实世界经验:简明扼要的总结

O'Donnell, Holly K; Simmons, Kimber M; Gitelman, Stephen E; Dex, Terry; Hill, Robert; Wieloch, Mattias; Zaccai, Julia; D'Souza, Jennifer; Ginchereau Sowell, France; Turnbull, James; Hood, Korey K

Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes

iGlarLixi 对未接受胰岛素治疗且血糖控制欠佳的 2 型糖尿病成人患者的持续血糖监测测量目标范围内时间的影响

Frías, Juan P; Ratzki-Leewing, Alexandria; Dex, Terry; Meneghini, Luigi; Rodrigues, Amélie; Shah, Viral N

Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes

接受替普利珠单抗治疗的 2 期 1 型糖尿病成人患者或患儿照护者的真实经历

O'Donnell, Holly K; Simmons, Kimber M; Gitelman, Stephen E; Dex, Terry; Hill, Robert; Wieloch, Mattias; Zaccai, Julia; D'Souza, Jennifer; Ginchereau Sowell, France; Turnbull, James; Hood, Korey K

Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes

在既往未接受过胰岛素治疗且血糖控制欠佳的 2 型糖尿病成人患者中,使用 iGlarLixi 治疗 16 周后的治疗满意度和血糖达标时间

Shah, Viral N; Dex, Terry; Meneghini, Luigi; Rodrigues, Amélie; Polonsky, William H

Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers

来自 LixiLan ONE CAN 胰岛素笔子研究的 iGlarLixi SoloStar 胰岛素笔易用性:2 型糖尿病患者及其医疗保健提供者的问卷调查结果

Yale, Jean-François; Roborel de Climens, Aude; Aggarwal, Naresh; Dex, Terry; Gerstein, Hertzel C; Harris, Stewart; Hramiak, Irene; Stewart, John; Leiter, Lawrence A

Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study

使用 iGlarLixi 治疗 2 型糖尿病患者的临床获益:一项患者水平模拟研究

Chauhan, Ankita; Samnaliev, Mihail; Ken-Opurum, Jennifer; Srinivas, Sistla S S; Mehta, Aashay M; Dex, Terry; Charland, Scott; Revel, Andrew; Preblick, Ronald

Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus

针对2型糖尿病患者,采用iGlarLixi强化治疗与替代治疗策略的预算影响分析

Ken-Opurum, Jennifer; Srinivas, Sistla S S; Jain, Divya; Shah, Tejaswinee; Samnaliev, Mihail; Dex, Terry; Charland, Scott; Revel, Andrew; Preblick, Ronald

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study

在接受基础胰岛素治疗后转为胰岛素治疗的2型糖尿病成人患者中,启动iGlarLixi与基础-餐时胰岛素治疗的比较:SoliComplex真实世界研究

Pantalone, Kevin M; Heller, Caroline; Lajara, Rosemarie; Lew, Elisheva; Li, Xuan; Dex, Terry; Kilpatrick, C Rachel

Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes

胰岛素格列净与利西拉肽的固定比例复方制剂(iGlarLixi)可改善2型糖尿病患者的β细胞功能。

Ferrannini, Ele; Niemoeller, Elisabeth; Dex, Terry; Servera, Soraly; Mari, Andrea

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US

在美国,对于基础胰岛素控制不佳的2型糖尿病患者,iGlarLixi 与预混胰岛素 BIAsp 30 的成本效益分析

Shao, Hui; Alsaleh, Abdul Jabbar Omar; Dex, Terry; Lew, Elisheva; Fonseca, Vivian